成人小说亚洲一区二区三区,亚洲国产精品一区二区三区,国产精品成人精品久久久,久久综合一区二区三区,精品无码av一区二区,国产一级a毛一级a看免费视频,欧洲uv免费在线区一二区,亚洲国产欧美中日韩成人综合视频,国产熟女一区二区三区五月婷小说,亚洲一区波多野结衣在线

立即打開(kāi)
阿斯利康-輝瑞合并交易有沒(méi)有科研價(jià)值

阿斯利康-輝瑞合并交易有沒(méi)有科研價(jià)值

Jennifer Reingold 2014年05月20日
數(shù)據(jù)分析公司根據(jù)這兩個(gè)制藥巨頭的專利情況進(jìn)行的對(duì)比分析顯示,兩者合并之后重疊程度最高的是心血管、神經(jīng)科學(xué)和心臟病學(xué)等領(lǐng)域的治療業(yè)務(wù)。

????輝瑞(Pfizer)擬與阿斯利康(AstraZeneca)合并(注:根據(jù)最新消息,阿斯利康已經(jīng)拒絕了輝瑞提高出價(jià)之后的收購(gòu)要約。)到底是為了避稅并削減成本,還是為了促進(jìn)互補(bǔ)性研究?也許兩者兼而有之。

????目前為止人們主要關(guān)注的是該交易的財(cái)務(wù)影響,但是科研方面值得進(jìn)一步關(guān)注。上周二,輝瑞公司首席執(zhí)行官伊恩?里德在英國(guó)國(guó)會(huì)工商專責(zé)委員會(huì)的聽(tīng)證會(huì)上表示,兩家公司“在心血管、代謝和腫瘤領(lǐng)域擁有互補(bǔ)的信息組合?!?/p>

????總部位于阿姆斯特丹的 The ANT Works是一家研發(fā)分析初創(chuàng)公司,這家公司從互動(dòng)的視角來(lái)分析了這兩家公司的科研情況(基于專利申請(qǐng)),以便評(píng)估里德的說(shuō)法。The ANT Works分析了57.000多份專利文件,包括1994年至2012年期間在美國(guó)、歐盟和日本的專利申請(qǐng)和授權(quán)專利。它向《財(cái)富》雜志獨(dú)家提供了自己分析得出的交互式圖像,展示了這兩家公司明顯重疊的領(lǐng)域(這將導(dǎo)致兩家公司裁員)以及各自獨(dú)特的優(yōu)勢(shì)。

????數(shù)據(jù)得出的主要結(jié)論是,輝瑞公司目前在研究領(lǐng)域處于主導(dǎo)地位,約80%的已注冊(cè)專利與研究領(lǐng)域相關(guān),而阿斯利康只有20%。The ANT Works首席戰(zhàn)略官托馬斯?格尼表示,這也意味著重疊程度最大的治療領(lǐng)域(如心血管、神經(jīng)科學(xué)和心臟病學(xué))將是阿斯利康最有可能裁員的領(lǐng)域。他說(shuō):“從科學(xué)的角度來(lái)看,如果進(jìn)行合并,很可能是阿斯利康削減研究人員?!边@也是阿斯利康到目前為止一直反對(duì)交易的主要原因(另一個(gè)原因是嫌要約價(jià)格太低)。阿斯利康首席執(zhí)行官帕斯卡爾?索利奧特與兩位首席科研人員也出席了聽(tīng)證會(huì)并表達(dá)意見(jiàn)。

????但圖形也顯示了阿斯利康將為輝瑞公司帶來(lái)的潛在全新藥物,這也確實(shí)證實(shí)了里德的說(shuō)法。這筆交易已經(jīng)引發(fā)了大量的爭(zhēng)議,不過(guò)用數(shù)據(jù)說(shuō)話總比只談?wù)我?。(?cái)富中文網(wǎng))

????Is the proposed merger of Pfizer and AstraZeneca a tax dodge, a cost-cutting cornucopia, or the ultimate in complementary research? It may well end up being all of the above.

????But since most of the attention thus far has been on the financial implications of the deal, it's worth taking a closer look at Pfizer CEO Ian Read's claim, made on Tuesday in a hearing before Britain's Business Select Committee, that the two companies have "complementary portfolios of information in cardiovascular, metabolic and oncology."

????Amsterdam-based The ANT Works, an R&D analytics startup, has put together an interactive visual look at both companies' research--based on patent filings--as a means by which to assess Read's claim. The ANT Works analyzed over 57.000 patent documents, which include patent applications and granted patents in the US, EU and Japan between 1994-2012. Provided exclusively to Fortune, the interactive map shows where there are clear overlaps--which it is fair to say will lend themselves to job cuts--and where each company has unique strengths.

????The main conclusion of the data is that Pfizer is by far the dominant player when it comes to research, with roughly 80% of the registered patents connected to research areas compared with AstraZeneca's 20%. That also implies that the therapeutic areas with the greatest overlap, such as cardiovascular, neurosciences, and cardiology will be most likely to be cut at AstraZeneca, says Thomas Gurney, CSO at The ANT Works. "If you look at this from the science perspective, he says, "if there is a merger, most likely the AstraZeneca scientists will lose." That's a big part of the reason why AstraZeneca is resisting so far (in addition to its assertion that the offer itself is too low). Indeed, AstraZeneca head Pascal Soriot showed up at the hearings with two of his head scientists in tow to make a point.

????But the graphic also shows areas where AstraZeneca offers access to a potential brand new pipeline for Pfizer, giving some credence to Read's claims as well. There's enough here for ammunition on either side—but it's nice to have data rather than simply politics in the mix.?

上圖為輝瑞和阿斯利康的57,000項(xiàng)專利涵蓋的所有技術(shù)領(lǐng)域。藍(lán)色代表輝瑞,黃色代表阿斯利康。圖片顯示,兩家公司重疊程度最大的是心血管、神經(jīng)科學(xué)和心臟病學(xué)等治療領(lǐng)域。圖片來(lái)源:The ANT Works
譯者:Lina

掃碼打開(kāi)財(cái)富Plus App
国产乱码一区二区三区| 久久精品国产99国产精2021| 日韩一区二区三区无码免费视频| 片多多免费观看高清电影| 久精品国产亚洲Av高清| 毛片免费观看久久精品| 中文AV网址在线观看| 国产精品久久久久久久hd| 国产玖玖玖精品视频| 国产精品无码AV在线毛片| 久久综合亚洲鲁鲁五月天| 真实国产乱子伦沙发睡午觉| 真实的国产乱ⅩXXX66| 国产区精品系列在线观看不卡| 久久精品国产亚洲av电影| 亚洲热在线视频亚洲永久精品网站| 亚洲美女ZOZO精品毛片| 免费人成视频在线播放| 精品人妻少妇嫩草AV无码专区| 99精品视频在线观看免费| 亚洲AV无码专区电影在线| 国产午夜无码精品免费看性色| 国产午夜福利精品一区二区三区| 99精品久久精品一区二区| 亚洲人成网址在线播放狼友| 国产高清国内精品福利| 怡红院成永久免费人视频新的| 日韩Ar中文字幕第一页| 欧美成aⅴ人高清免费| 午夜精品久久久久久中宇| 精品无人区无码乱码毛片国产| 人人妻人人澡人人爽精品日本| 欧美亚洲国产日韩欧美4p| 免费很黄很色的裸乳| 日韩女同中文字幕永久在线| 国产成人一区二区三区视频免费| 欧美成人午夜一区二区三区| 久久久久久精品免费无码无| 久久久久无码精品国产| 成人免费一区二区无码视频| 无码人妻精品一区二区蜜桃网站|